Improved survival with vemurafenib in melanoma with BRAF V600E mutation
Proto-Oncogene Proteins B-raf
Vemurafenib produced improved rates of overall and progression-free survival in patients with previously untreated melanoma with the BRAF V600E mutation. (Funded by Hoffmann-La Roche; BRIM-3 ClinicalTrials.gov number, NCT01006980.).